---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023724"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:47:39.991834+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences Q2 net loss $2.5M; EB-003 dual mechanism disclosed, IND on track for early 2026

## Summary
- Net loss $2.5M ($0.97/shr) vs $1.9M ($3.72/shr) in Q2 2024; cash $2.8M at June 30.
- Raised $4.9M net proceeds in first half 2025 via financing tools.
- EB-003 reveals dual agonism at 5-HT2A (partial) and 5-HT1B receptors, a novel class.
- IND submission for EB-003 expected early 2026; preclinical models show PTSD and depression efficacy.
- Expanded IP portfolio: new patent filed, allowance for mescaline-derivative and tryptamine patents.

## SEC filing metadata
- accession: 0001641172-25-023724
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000164117225023724/0001641172-25-023724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000164117225023724/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023724
- JSON: https://secwatch.observer/filing/0001641172-25-023724.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.